Subtype
Endocrine Mucin-Producing Sweat Gland Carcinoma
CI-CAN-00005156EMPSGCExplore in graph →
1 active trials
Loading cancer entity…
Subtype
CI-CAN-00005156EMPSGCExplore in graph →
Clinical trials
1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials